|
| Clinical response | Clinical remission | Follow-up | Study | Study type | Country | N | Severity | Donor | Route | Fresh/frozen |
|
| dFMT: 18/38 (47%); aFMT: 6/35 (17%), at week 8 | dFMT: 21/38 (55%); aFMT: 8/35 (23%), at week 8 | 8 weeks | Costello et al. [20] | UC | Australia | 73 | Mild to moderate | Unrelated | Colonoscopy and enema (lower) | Frozen |
| FMT: 9 (24%); placebo: 2 (5%) at week 7 | FMT: 15 (39%); placebo: 9 (24%) at week 7 | 6 weeks | Moayyedi et al. [21] | UC | Canada | 75 | Active | Unrelated | Retention enema (lower) | Fresh or frozen |
| FMT: 18 (44%); placebo: 8 (20%) at week 8 | FMT: 22 (54%); placebo: 9 (23%) at week 8 | 8 weeks | Paramsothy et al. [22] | UC | Australia | 81 | Mild to moderate | Unrelated | Colonoscopy and enema (lower) | Frozen |
| dFMT: 6/23 (26.1%); aFMT: 8/25 (32%), at week 6; dFMT: 7/23 (30.4%); aFMT: 8/25 (32%), at week 12 | dFMT: 10/23 (43.5%); aFMT: 13/25 (52.0%), at week 6; dFMT: 11/23 (47.8%); aFMT: 13/25 (52%), at week 12 | 12 weeks | Rossen et al. [23] | UC | Netherlands | 48 | Mild to moderate | Relatives, partners, or volunteers | Nasoduodenal tube (upper) | Fresh |
| FMT: 7/8 (87.5%); sham FMT: 4/9 (44.4%), at week 10; FMT: 4/8 (50.0%); sham FMT: 3/9 (33.3%), at week 24 | — | 12 weeks | Sokol et al. [24] | CD | France | 17 | Active | Unrelated | Colonoscopy (lower) | Fresh |
| FMT: 27/31 (87.1%); placebo: 20/30 (66.7%) at week 48 | — | 48 weeks | Sood et al. [25] | UC | India | 61 | Active | Unrelated | Colonoscopy infusion and enema (lower) | Fresh or frozen |
| FMT: 3/10 (30%); FMTP: 4/10 (40%) at week 12 | FMT: 7/10 (70%); FMTP: 6/10 (60%) at week 12 | 12 weeks | Wei et al. [26] | UC | China | 20 | Mild to moderate | Unrelated | Colonoscopy (lower) | Fresh |
| Gastroscopy: 10/13 (76.9%); colonoscopy: 11/14 (78.6%) at week 2 | Gastroscopy: 9/13 (69.2%); colonoscopy: 9/14 (64.3%) at week 2 | 8 weeks | Yang et al. [27] | CD | China | 27 | Active | Relatives, partners, or volunteers | Gastroscopy or colonoscopy (upper or lower) | Fresh |
| cFMT: 2/6 (33%); placebo: 0/6 (0%) at week 12 | cFMT: 3/6 (50%); placebo: 1/6 (17%) at week 12 | 36 weeks | Crothers et al. [28] | UC | USA | 17 | Mild to moderate | Unrelated | Colonoscopy infusion and oral (lower and upper) | Frozen and capsules |
| FMT: 9/10 (90%); control: 5/10 (50%) at week 8 | — | 6–38 months | Fang et al. [29] | UC | China | 20 | Active | Unrelated | Colonoscopy (lower) | Fresh |
| FMT: 2/17 (11.8%); FMT + UCED: 4/19 (21.1%); UCED: 6/15 (40.0%) at week 8 | FMT: 6/17 (35.3%); FMT + UCED: 8/19 (42.1%); UCED: 9/15 (60.0%) at week 8 | 12 weeks | Sarbagili Shabat et al. [30] | UC | Israel | 51 | Mild to moderate | Unrelated | Colonoscopy and enema (lower) | Frozen |
| FMT: 3/8 (37.5%); 5-ASA: 4/8 (50%) at week 12 | FMT: 5/8 (62.5%); 5-ASA: 5/8 (62.5%) at week 12 | 12 weeks | Schierová et al. [31] | UC | Czech republic | 16 | Active | Unrelated | Enema (lower) | Frozen |
| FMT: 20/30 (66.67%); control: 12/30 (40.00%) at week 4 | — | 3 months | Chen et al. [32] | UC | China | 60 | NR | Unrelated | Enema (lower) | Fresh or frozen |
| FMT: 48/50 (96%); 5-ASA: 35/50 (70%) at week 2 | — | NR | Zhang et al. [33] | UC | China | 100 | NR | Relatives, partners | Enema (lower) | NR |
|
